U.S. senators criticize SF company over Super Bowl commercial
The Brief
Hims and Hers is a telehealth firm based in San Francisco
U.S. Senators Dick Durbin and Roger Marshall are criticizing a Super Bowl commercial by the company
SAN FRANCISCO - Outside the game, commercials are a big part of Super Bowl Sunday. Companies pay large amounts of money for their advertisements. One company based in the Bay Area has already released its commercial, and it's drawing criticism from lawmakers in Washington.
Hims and Hers, headquartered in San Francisco, is a telehealth firm, and in their latest ad, they promote a weight-loss drug similar to Ozempic.
U.S. Senators Dick Durbin (D-IL) and Roger Marshall (R-KS) sent a bipartisan letter to the FDA about the advertisement, accusing the ad of misleading patients by "omitting any safety or side effect information when prompting a specific type of weight loss medication," according to a statement on Durbin's website.
"An upcoming Super Bowl advertisement…appears to showcase a company's ability to prescribe and dispense GLP-1 medications to patients, including with text and claims about weight loss drugs, and imagery of an injection pen with distinctive characteristics reflective of an existing brand-name medication. However, nowhere in this promotion is there any side effect disclosure, risk, or safety information as would be typically required in a pharmaceutical advertisement," the senators wrote in part.
The other side
KTVU reached out to the San Francisco-based firm about the controversy.
"We agree with the Senators, Durbin and Marshall, on the value of compounding and telehealth when it comes to expanding much-needed access to personalized care. We are complying with existing law and are happy to continue working with Congress and the new Administration to fix the broken health system and ensure that patients have choices for quality, safe, and affordable healthcare," Hims and Hers said in response.
The Source
Senator Durbin's website, Hims and Hers spokesperson
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target for Eli Lilly & Company (NYSE:LLY) on June 13 ahead of the 85th Annual Meeting of the American Diabetes Association. Pixabay/Public Domain The firm outlined a number of crucial data presentations that Eli Lilly & Company (NYSE:LLY) is expected to provide at the next meeting. One of these is the full description of the ACHIEVE-1 study, which is the first phase 3 trial from the late-stage clinical program of orforglipron. Bernstein is especially keen to acquire more information on the negative event profile and discontinuation rates, even if topline data is already available. Additionally, Eli Lilly & Company (NYSE:LLY) will provide information about its muscle-wasting medication, bimagrumab. When paired with tirzepatide, this will be the first clinical data reported for an anti-muscle wasting agent used in conjunction with a GLP-1 receptor agonist, possibly hinting at future use cases. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Connectez-vous pour accéder à votre portefeuille
Business Insider
an hour ago
- Business Insider
Why Is Impact BioMedical Stock (IBO) Up 200% Today?
Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr Ashleys Limited. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These two companies have agreed to a reverse merger that will see Dr Ashleys Limited acquire Impact BioMedical, with the combined company trading under the Dr Ashleys Limited name. The Dr Ashleys management team will lead the combined company and will also create a new Board of Directors. Dr. Kanans Visvanats, director of Dr. Ashleys Limited, said, 'By integrating Impact Biomedical's impressive IP portfolio into our R&D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health.' IBO Stock Movement Today
Business Wire
2 hours ago
- Business Wire
Simple Online Healthcare launches in Denmark as revenue triples
GLASGOW, Scotland--(BUSINESS WIRE)-- Simple Online Healthcare has launched in Denmark after tripling its revenue. Headquartered in Glasgow, Simple Online is one of the UK's fastest-growing healthcare groups, offering scalable, regulated digital clinics across the UK, Germany, and Australia. In the UK, it operates as Simple Online Pharmacy. Led by CEO and Co-founder Addy Mohammed, Simple Online Healthcare reported revenue of £66 million in the year to 28th February 2025 [2024: £20.6m], and marked its 10-year anniversary in April with record monthly revenue of £10 million. Addy Mohammed said: 'We're proud of how far we've come in our first ten years, and we think it's notable that we've remained fully self-funded during that time. Denmark represents our third international market, and we are planning further expansion over the next twelve months.' CFO Michael Hope said: 'We've scaled rapidly in recent years, investing across geography, supply chain, technology, and talent. Financial discipline and patient retention are underpinning our growth, allowing us to invest in new markets and our digital platform, creating an improved patient experience, differentiation, and operational efficiencies.' Addy Mohammed co-founded Simple Online Healthcare alongside university friend Karim Nassar, who is Simple Online's Chief Growth Officer, in 2015, building on their experience of owning and operating community pharmacies across Scotland to offer consumers a convenient patient-first pharmacy service with medications delivered direct to their door. The company has a headcount of 130, and plans to make additional hires this year. Simple Online was one of the first providers of weight loss medications in the UK. The business has invested significantly in its weight management programme and is one of the leading providers of GLP-1 medications Wegovy and Mounjaro, which are prescribed alongside comprehensive holistic weight management support. 'We know global healthcare systems are struggling,' says Mohammed, 'with the top issues being long waiting times, insufficient staff, and cost of treatments. We are using technology to give patients quick and discrete access to the care they need, at a much lower cost than traditional healthcare models. Combining technology with a multi-disciplinary team of health professionals, we can provide the personalised level of care you'd receive in a community pharmacy.' Simple Online has invested over £2 million into technology and systems during 2025, with Mohammed commenting: 'Digital healthcare is evolving rapidly, and we're continuing to invest in technology to enhance the patient journey and deliver best-in-class care.' 'Our vision is to make healthcare affordable and accessible,' says Mohammed. 'We support our patients with the personalised tools and knowledge to make long-term lifestyle changes.' The global online pharmacy market is valued at almost £100 billion in 2025, and is forecast to grow to around £400 billion by 2033. Simple Online's board includes former Skyscanner CFO Shane Corstorphine, and the company is set to further strengthen its executive leadership team this year.
